Kymera Therapeutics (NASDAQ: KYMR) grants CBO new options and RSUs

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. reported that Chief Business Officer Noah Goodman received new equity awards. On March 2, 2026, he was granted a stock option for 18,450 shares at an exercise price of $0.00 per share and 9,225 shares of common stock in the form of restricted stock units. Following the RSU grant, his direct common stock holdings increased to 59,306.438 shares. The RSUs vest in four equal annual installments after March 2, 2026, while the option vests in 48 equal monthly installments after that date, in each case conditioned on continued employment.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Goodman Noah

Role Chief Business Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	18,450	$0.00	--
Grant/Award	Common Stock	9,225	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 18,450 shares (Direct); Common Stock — 59,306.438 shares (Direct)

Footnotes (1)

1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date. The shares underlying this stock option shall vest in fourty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Goodman Noah

(Last) (First) (Middle)

500 NORTH BEACON STREET

4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		9,225(1)	A	$0	59,306.438	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$90.1	03/02/2026		A		18,450		(2)	03/01/2036	Common Stock	18,450	$0	18,450	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.

2. The shares underlying this stock option shall vest in fourty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.

	/s/ Bruce Jacobs, as Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Kymera Therapeutics (KYMR) report for Noah Goodman?

Kymera Therapeutics reported that Chief Business Officer Noah Goodman received equity awards, not an open-market trade. He was granted 18,450 stock options and 9,225 restricted stock units on March 2, 2026, as part of his compensation package.

How many Kymera (KYMR) stock options were granted to the CBO on March 2, 2026?

Noah Goodman received a grant of 18,450 stock options on March 2, 2026. These options vest in 48 equal monthly installments starting after March 2, 2026, subject to his continued employment with Kymera Therapeutics through each vesting date.

What restricted stock unit (RSU) award did Kymera (KYMR) grant to Noah Goodman?

Kymera granted Noah Goodman 9,225 restricted stock units, each representing one share of common stock. The RSUs vest in four equal annual installments following March 2, 2026, provided he remains employed with the company through each applicable vesting date.

At what price were the Kymera (KYMR) stock options granted to the CBO?

The 18,450 stock options granted to Noah Goodman carry an exercise price of $0.00 per share. This structure reflects a compensatory award, with value realized over time as the options vest according to the monthly vesting schedule.

How did the RSU grant affect Noah Goodman’s Kymera (KYMR) share holdings?

After the 9,225-share RSU grant, Noah Goodman’s direct holdings of Kymera common stock totaled 59,306.438 shares. These RSUs will convert into shares upon vesting and settlement, assuming he satisfies the continued employment conditions.

What are the vesting conditions for Kymera (KYMR) RSUs granted to the CBO?

The 9,225 RSUs vest in four equal annual installments after March 2, 2026. Each installment requires Noah Goodman to remain employed with Kymera Therapeutics through the applicable vesting date before shares are delivered.